Error message

  • There was an error processing your request.
  • There was an error processing your request.

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Jun 02, 2024 10:55 ET
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker study to date...
Jun 02, 2024 10:00 ET
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster...
Jun 02, 2024 10:00 ET
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Ther
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases,...
Jun 02, 2024 10:00 ET
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared two scientific poster presentations from the 2024 American Society of...
Jun 02, 2024 09:51 ET
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, both dates inclusive (the “Class Period”), have until July 22, 2024 to seek appointment...
Jun 02, 2024 09:01 ET
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by...
Jun 02, 2024 08:56 ET
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software availability of NVIDIA AI Enterprise-IGX with NVIDIA Holoscan on the NVIDIA IGX™ platform. Together, they...
Jun 02, 2024 08:52 ET
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
COMPUTEX -- NVIDIA today announced that the world’s leaders in robot development are adopting the NVIDIA Isaac™ robotics platform for the research, development and production of the next generation of AI-enabled autonomous machines and robots. BYD...
Jun 02, 2024 08:44 ET
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
COMPUTEX -- NVIDIA today announced that major Taiwanese electronics makers are using the company’s technology to transform their factories into more autonomous facilities with a new reference workflow. The workflow combines NVIDIA Metropolis vision...
Jun 02, 2024 08:41 ET
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
COMPUTEX -- NVIDIA today announced new NVIDIA RTX™ technology to power AI assistants and digital humans running on new GeForce RTX™ AI laptops. NVIDIA unveiled Project G-Assist — an RTX-powered AI assistant technology demo that provides...
Jun 02, 2024 08:35 ET
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
COMPUTEX -- NVIDIA and the world’s top computer manufacturers today unveiled an array of NVIDIA Blackwell architecture-powered systems featuring Grace CPUs, NVIDIA networking and infrastructure for enterprises to build AI factories and data centers...
Jun 02, 2024 08:32 ET
NVIDIA Supercharges Ethernet Networking for Generative AI
COMPUTEX -- NVIDIA today announced widespread adoption of the NVIDIA Spectrum™-X Ethernet networking platform as well as an accelerated product release schedule. CoreWeave, GMO Internet Group, Lambda, Scaleway, STPX Global and Yotta are among...
Jun 02, 2024 08:23 ET
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
Robbins Geller Rudman & Dowd LLP announces that the GoodRx class action lawsuit seeks to represent purchasers or acquirers of GoodRx Holdings, Inc. (NASDAQ: GDRX) common stock between September 23, 2020 and November 8, 2022, inclusive (the “Class...
Jun 02, 2024 08:13 ET
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
COMPUTEX -- NVIDIA today announced that the world’s 28 million developers can now download NVIDIA NIM™ — inference microservices that provide models as optimized containers — to deploy on clouds, data centers or workstations, giving them the...
Jun 02, 2024 08:11 ET
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
COMPUTEX -- NVIDIA today announced the general availability of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans, as well as new generative AI breakthroughs coming soon to the platform. Companies in...
Jun 02, 2024 08:00 ET
CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations
In response to the ongoing volatility in the cryptocurrency markets, CryptoHeap, a leading provider of cryptocurrency staking services, has introduced a strategic blueprint designed to optimize staking outcomes for investors during these...
Jun 02, 2024 08:00 ET
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of...
Jun 02, 2024 04:00 ET
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after...
Jun 02, 2024 02:00 ET
ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth
ePac Flexible Packaging, founded in 2016 as the world's first all-digital flexible packaging company, just turned 8 years old in May of this year. So it’s fair to ask: How is ePac doing with its disruptive business model? From 2016 through 2022...
Jun 01, 2024 21:00 ET
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) in the United States District Court for...